Health Care·Biotechnology·$2.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.15 | N/A | -117.60% |
management commentary, guidance changes, and full analysis available with Pro.
| -117.60% |
Tone: Defensive
Management expressed a cautious outlook, emphasizing the need for continued investment in growth initiatives. They did not provide specific guidance for future performance.
Management did not provide specific guidance for the upcoming quarters.
The company is focusing on long-term growth despite current challenges.
Veracyte's earnings report shows a significant miss on EPS, which may raise concerns among investors about the company's current financial health. The stock reacted negatively, declining by 1.13%. The lack of guidance adds uncertainty to future performance, leaving investors looking for more clarity in upcoming quarters.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ONEOK INC NEW
Feb 24, 2020